Ikarian Capital
Latest statistics and disclosures from Ikarian Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KRYS, XBI, ALNY, CRNX, SRPT, and represent 30.31% of Ikarian Capital's stock portfolio.
- Added to shares of these 10 stocks: AZN (+$21M), CORT (+$18M), IRON (+$17M), FDMT (+$16M), VKTX (+$16M), CRBP (+$14M), XBI (+$14M), MDGL (+$14M), INSM (+$13M), MGNX (+$12M).
- Started 26 new stock positions in CRVO, VRDN, VERU, VKTX, MGNX, CYBN, AZN, BHVN, ARQT, LENZ.
- Reduced shares in these 10 stocks: ARGX (-$86M), CRSP (-$45M), LLY (-$41M), , CYTK (-$28M), NUVL (-$23M), LBPH (-$21M), , SRPT (-$19M), .
- Sold out of its positions in ABBV, ACRS, RCUS, ARGX, AUTL, BDTX, CLDX, CHRS, DYN, EWTX.
- Ikarian Capital was a net seller of stock by $-222M.
- Ikarian Capital has $912M in assets under management (AUM), dropping by -14.58%.
- Central Index Key (CIK): 0001778253
Tip: Access up to 7 years of quarterly data
Positions held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ikarian Capital
Ikarian Capital holds 100 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Krystal Biotech Put Option (KRYS) | 9.3 | $85M | -7% | 475k | 177.93 |
|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 7.3 | $66M | +27% | 700k | 94.89 |
|
| Alnylam Pharmaceuticals (ALNY) | 5.1 | $46M | +15% | 309k | 149.45 |
|
| Crinetics Pharmaceuticals In (CRNX) | 4.9 | $45M | +22% | 953k | 46.81 |
|
| Sarepta Therapeutics (SRPT) | 3.8 | $35M | -35% | 268k | 129.46 |
|
| Corcept Therapeutics Incorporated Put Option (CORT) | 3.5 | $32M | +134% | 1.3M | 25.19 |
|
| Tarsus Pharmaceuticals (TARS) | 3.2 | $30M | +31% | 810k | 36.35 |
|
| Disc Medicine (IRON) | 3.2 | $29M | +141% | 472k | 62.26 |
|
| Soleno Therapeutics (SLNO) | 3.0 | $28M | +5% | 647k | 42.80 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.4 | $22M | +185% | 559k | 39.24 |
|
| Astrazeneca Sponsored Adr Call Option (AZN) | 2.3 | $21M | NEW | 309k | 67.75 |
|
| Bridgebio Pharma (BBIO) | 2.3 | $21M | +41% | 671k | 30.92 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 2.0 | $18M | -16% | 866k | 20.67 |
|
| Biomea Fusion Put Option (BMEA) | 1.9 | $18M | -7% | 1.2M | 14.95 |
|
| Cytokinetics Com New (CYTK) | 1.9 | $17M | -61% | 245k | 70.11 |
|
| Amgen Call Option (AMGN) | 1.9 | $17M | +71% | 60k | 284.32 |
|
| 4d Molecular Therapeutics In Put Option (FDMT) | 1.8 | $16M | NEW | 515k | 31.86 |
|
| Viking Therapeutics Put Option (VKTX) | 1.8 | $16M | NEW | 200k | 82.00 |
|
| Alpine Immune Sciences | 1.6 | $14M | -25% | 364k | 39.64 |
|
| Madrigal Pharmaceuticals Put Option (MDGL) | 1.5 | $14M | NEW | 51k | 267.04 |
|
| Insmed Com Par $.01 (INSM) | 1.4 | $13M | +234617% | 469k | 27.13 |
|
| Macrogenics (MGNX) | 1.4 | $12M | NEW | 842k | 14.72 |
|
| Biohaven Call Option (BHVN) | 1.3 | $12M | NEW | 224k | 54.69 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.3 | $12M | NEW | 654k | 17.76 |
|
| Praxis Precision Medicines I Com New (PRAX) | 1.3 | $12M | -4% | 190k | 61.02 |
|
| Aerovate Therapeutics (AVTE) | 1.2 | $11M | NEW | 368k | 29.57 |
|
| Lantheus Holdings Inc Common Stock Usd 0.01 Call Option (LNTH) | 1.2 | $11M | -40% | 170k | 62.24 |
|
| Acelyrin (SLRN) | 1.2 | $11M | -32% | 1.6M | 6.75 |
|
| Annexon (ANNX) | 1.1 | $10M | -46% | 1.4M | 7.17 |
|
| Astria Therapeutics (ATXS) | 1.1 | $9.8M | +85% | 694k | 14.07 |
|
| Marinus Pharmaceuticals Com New (MRNS) | 1.0 | $9.5M | +41% | 1.1M | 9.04 |
|
| Alexandria Real Estate Equities Put Option (ARE) | 1.0 | $9.4M | 73k | 128.91 |
|
|
| Immunovant (IMVT) | 1.0 | $8.9M | -60% | 277k | 32.31 |
|
| Catalyst Pharmaceutical Partners (CPRX) | 0.9 | $8.3M | +2% | 518k | 15.94 |
|
| Rocket Pharmaceuticals (RCKT) | 0.9 | $8.0M | -23% | 297k | 26.94 |
|
| Apellis Pharmaceuticals (APLS) | 0.9 | $7.9M | -26% | 135k | 58.78 |
|
| Moonlake Immunotherapeutics Class A Ord Put Option (MLTX) | 0.9 | $7.9M | -21% | 158k | 50.23 |
|
| Nuvalent Inc-a (NUVL) | 0.8 | $7.6M | -75% | 102k | 75.09 |
|
| Pyxis Oncology Common Stock (PYXS) | 0.8 | $7.1M | NEW | 1.7M | 4.26 |
|
| Abeona Therapeutics Com New (ABEO) | 0.8 | $6.9M | +59% | 956k | 7.25 |
|
| Tourmaline Bio (TRML) | 0.7 | $6.6M | NEW | 288k | 22.90 |
|
| Lyra Therapeutics (LYRA) | 0.7 | $6.6M | -15% | 1.1M | 6.22 |
|
| Verona Pharma Sponsored Ads (VRNA) | 0.7 | $6.0M | +2% | 375k | 16.09 |
|
| Annovis Bio Put Option (ANVS) | 0.7 | $6.0M | +14661% | 502k | 11.90 |
|
| Arcutis Biotherapeutics (ARQT) | 0.6 | $5.8M | NEW | 590k | 9.91 |
|
| Cybin Ord (CYBN) | 0.6 | $5.8M | NEW | 14M | 0.41 |
|
| Cervomed (CRVO) | 0.6 | $5.5M | NEW | 237k | 23.30 |
|
| Structure Therapeutics Sponsored Ads Put Option (GPCR) | 0.6 | $5.2M | +742% | 122k | 42.86 |
|
| Xenon Pharmaceuticals (XENE) | 0.5 | $4.6M | -30% | 107k | 43.05 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.5 | $4.5M | -27% | 1.6M | 2.84 |
|
| Nurix Therapeutics (NRIX) | 0.5 | $4.4M | NEW | 300k | 14.70 |
|
| Rapt Therapeutics (RAPT) | 0.5 | $4.4M | +729% | 488k | 8.98 |
|
| Wave Life Sciences SHS (WVE) | 0.4 | $3.6M | NEW | 590k | 6.17 |
|
| Cabaletta Bio Put Option (CABA) | 0.4 | $3.4M | -51% | 200k | 17.06 |
|
| Larimar Therapeutics (LRMR) | 0.4 | $3.3M | -27% | 439k | 7.59 |
|
| Miragen Therapeutics Put Option (VRDN) | 0.3 | $3.1M | NEW | 179k | 17.51 |
|
| Jasper Therapeutics Com New (JSPR) | 0.3 | $3.1M | NEW | 105k | 29.36 |
|
| Aeon Biopharma Cl A (AEON) | 0.3 | $3.0M | 258k | 11.60 |
|
|
| Mind Medicine Mindmed Com New (MNMD) | 0.3 | $2.8M | -50% | 298k | 9.40 |
|
| Ventyx Biosciences (VTYX) | 0.3 | $2.8M | +8483% | 508k | 5.50 |
|
| Kodiak Sciences (KOD) | 0.3 | $2.5M | +15% | 477k | 5.26 |
|
| Uniqure Nv SHS (QURE) | 0.3 | $2.4M | +198% | 469k | 5.20 |
|
| Ibio Con New (IBIO) | 0.3 | $2.4M | NEW | 600k | 4.06 |
|
| Nuvation Bio Com Cl A (NUVB) | 0.3 | $2.3M | -48% | 633k | 3.64 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.2 | $2.2M | NEW | 413k | 5.42 |
|
| Immunic (IMUX) | 0.2 | $2.1M | +258% | 1.6M | 1.32 |
|
| Lenz Therapeutics (LENZ) | 0.2 | $1.9M | NEW | 85k | 22.33 |
|
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.2 | $1.8M | NEW | 1.4M | 1.25 |
|
| Voyager Therapeutics (VYGR) | 0.2 | $1.7M | -40% | 181k | 9.31 |
|
| Iteos Therapeutics (ITOS) | 0.2 | $1.4M | -70% | 101k | 13.64 |
|
| Allakos (ALLK) | 0.1 | $1.2M | +293% | 933k | 1.26 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.1 | $1.1M | +2% | 484k | 2.27 |
|
| Inflarx Nv (IFRX) | 0.1 | $1.1M | +2% | 705k | 1.54 |
|
| Acumen Pharmaceuticals (ABOS) | 0.1 | $1.1M | -15% | 266k | 4.05 |
|
| Roivant Sciences SHS (ROIV) | 0.1 | $1.1M | -33% | 101k | 10.54 |
|
| Glycomimetics Put Option (GLYC) | 0.1 | $1.0M | NEW | 346k | 3.00 |
|
| Avalo Therapeutics Com New (AVTX) | 0.1 | $1.0M | NEW | 47k | 21.75 |
|
| Avrobio Ord (AVRO) | 0.1 | $965k | +4% | 754k | 1.28 |
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $834k | 466k | 1.79 |
|
|
| Protara Therapeutics Com Stk (TARA) | 0.1 | $813k | +7% | 203k | 4.01 |
|
| Kezar Life Sciences (KZR) | 0.1 | $784k | 869k | 0.90 |
|
|
| Elevation Oncology (ELEV) | 0.1 | $760k | -87% | 148k | 5.13 |
|
| Nyxoah S A SHS (NYXH) | 0.1 | $684k | NEW | 51k | 13.49 |
|
| Female Health (VERU) | 0.1 | $663k | NEW | 946k | 0.70 |
|
| Karyopharm Therapeutics (KPTI) | 0.1 | $618k | +2% | 409k | 1.51 |
|
| Terns Pharmaceuticals (TERN) | 0.1 | $581k | -46% | 89k | 6.56 |
|
| Immatics SHS (IMTX) | 0.1 | $519k | 49k | 10.51 |
|
|
| Anebulo Pharmaceuticals (ANEB) | 0.0 | $453k | 158k | 2.87 |
|
|
| Tempest Therapeutics (TPST) | 0.0 | $413k | 106k | 3.91 |
|
|
| Q32 Bio (QTTB) | 0.0 | $381k | NEW | 22k | 17.04 |
|
| Hookipa Pharma Inc equity (HOOK) | 0.0 | $378k | 531k | 0.71 |
|
|
| Relmada Therapeutics (RLMD) | 0.0 | $188k | 40k | 4.65 |
|
|
| Chemomab Therapeutics Sponsored Ads (CMMB) | 0.0 | $166k | 213k | 0.78 |
|
|
| Stoke Therapeutics (STOK) | 0.0 | $92k | -43% | 6.8k | 13.50 |
|
| Brainstorm Cell Therapeutics Com New (BCLI) | 0.0 | $51k | 90k | 0.56 |
|
|
| Synlogic Com New (SYBX) | 0.0 | $37k | 20k | 1.79 |
|
|
| Finch Therapeutics Group Com New (FNCH) | 0.0 | $18k | 6.9k | 2.63 |
|
|
| Tyra Biosciences (TYRA) | 0.0 | $8.2k | -98% | 501.00 | 16.40 |
|
| Aslan Pharmaceuticals Spon Ads New (ASLN) | 0.0 | $6.3k | 35k | 0.18 |
|
|
| Longboard Pharmaceuticals In (LBPH) | 0.0 | $5.1k | -99% | 236.00 | 21.60 |
|
Past Filings by Ikarian Capital
SEC 13F filings are viewable for Ikarian Capital going back to 2019
- Ikarian Capital 2024 Q1 restated filed May 17, 2024
- Ikarian Capital 2024 Q1 filed May 15, 2024
- Ikarian Capital 2023 Q4 filed Feb. 14, 2024
- Ikarian Capital 2023 Q3 filed Nov. 14, 2023
- Ikarian Capital 2023 Q2 filed Aug. 14, 2023
- Ikarian Capital 2023 Q1 filed May 15, 2023
- Ikarian Capital 2022 Q4 filed Feb. 14, 2023
- Ikarian Capital 2022 Q3 filed Nov. 14, 2022
- Ikarian Capital 2022 Q2 filed Aug. 12, 2022
- Ikarian Capital 2022 Q1 filed May 13, 2022
- Ikarian Capital 2021 Q4 filed Feb. 14, 2022
- Ikarian Capital 2021 Q3 filed Nov. 15, 2021
- Ikarian Capital 2021 Q1 restated filed Aug. 18, 2021
- Ikarian Capital 2021 Q2 restated filed Aug. 18, 2021
- Ikarian Capital 2021 Q2 filed Aug. 16, 2021
- Ikarian Capital 2021 Q1 filed May 17, 2021